Forazolines, compositions thereof and uses thereof
An isolated compound of Formula I and salts thereof are provided: wherein X is Cl or Br. A compound isolated from Actinomadura and having a chemical formula of C 43 H 69 ClN 4 O 10 S 2 or C 43 H 69 BrN 4 O 10 S 2 is also provided. Compositions including the compounds and methods of using the compounds to treat fungal infections including those such as Candida are also disclosed.
1. A pharmaceutical composition comprising an effective amount of a compound of Formula I:
or pharmaceutically acceptable salt thereof for treating a fungal infection in a mammal, wherein X is Cl or Br; and
a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , formulated for oral, parenteral, nasal, or topical administration.
3. The pharmaceutical composition of claim 1 , wherein the mammal is human.
4. The pharmaceutical composition of claim 1 , further comprising amphotericin B, ketoconazole, terbinafine, nystatin, fluconazole, itraconazole, or nystatin.
5. The pharmaceutical composition of claim 1 , wherein the compound of Formula I has the Formula IA:
wherein X is Cl or Br.
6. The pharmaceutical composition of claim 5 , wherein the mammal is human.
7. The pharmaceutical composition of claim 1 , wherein the compound of Formula I has the Formula IB:
8. The pharmaceutical composition of claim 7 , wherein the mammal is human.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises an effective amount of the compound or pharmaceutically acceptable salt thereof for treating a Candida infection.
10. The pharmaceutical composition of claim 9 , wherein the mammal is human.
11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises an effective amount of the compound or pharmaceutically acceptable salt thereof for treating a Candida albicans infection in a human.
12. A pharmaceutical composition comprising an effective amount of a compound of Formula I:
or pharmaceutically acceptable salt thereof for treating a fungal infection in a mammal, wherein X is Cl or Br; and
an isotonic aqueous solution.
13. The pharmaceutical composition of claim 12 , formulated for parenteral administration.
14. The pharmaceutical composition of claim 12 , wherein the mammal is human.
15. The pharmaceutical composition of claim 12 , wherein the compound of Formula I has the Formula IA:
wherein X is Cl or Br.
16. The pharmaceutical composition of claim 12 , wherein the compound of Formula I has the Formula IB:
17. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises an effective amount of the compound or pharmaceutically acceptable salt thereof for treating a Candida infection.
18. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition comprises an effective amount of the compound or pharmaceutically acceptable salt thereof for treating a Candida albicans infection.
19. A pharmaceutical composition comprising an effective amount of a compound of Formula I:
or pharmaceutically acceptable salt thereof for treating a fungal infection in a mammal, wherein X is Cl or Br; and
one or more of cetyl esters wax, cetyl alcohol, white wax, glyceryl monostearate, propylene glycol monostearate, methyl stearate, benzyl alcohol, sodium lauryl sulfate, glycerin, mineral oil, carbomer, ethyl alcohol, acrylate adhesives, polyisobutylene adhesives, and silicone adhesives.
20. The pharmaceutical composition of claim 19 , wherein the mammal is human.
21. The pharmaceutical composition of claim 19 , further comprising amphotericin B, ketoconazole, terbinafine, nystatin, fluconazole, itraconazole, or nystatin.